KDM2B, and EZH2 expression in myeloid cell lines and primary MDS marrow cells.

<p>Expression of KDM2B, <b>A</b>) and EZH2, <b>B</b>) in marrow cells from MDS patients (n = 21) and healthy controls (n = 11) (p = 0.0126 and <0.001, respectively, Student t-test). <b>C</b>) Direct correlation of KDM2B and EZH2 (p = 0.0131, R² = 0.2830, 95%CI 0.1300–0.7837), <b>D</b>) Inverse correlation of let-7b and KDM2B, <b>E</b>) Inverse correlation of let-7b and EZH2. <b>F</b>) Immunohistochemistry (IHC) for EZH2 on marrow sections from 6 patients with MDS and linkage to Let-7b levels as determined by miRNA microarray. BM CD34+ from MDS patients expressing higher levels of let-7b expressed lower levels of EZH2, and vice versa. <b>G</b>) EZH2 immunohistochemistry on a normal marrow with Periodic Acid-Schiff stain as the counter stain was used for the purpose of lineage differentiation. The large cells with brown nuclear staining are a morphologically normal megakaryocytes, positive for EZH2. Of the remaining cells, eosinophilic cells of myeloid lineage and show low level variable reactivity for EZH2, while the remaining erythroid cells show dim to moderate reactivity for EZH2, underscoring the relevance of lineage specific EZH2 expression.